Literature DB >> 15144899

Functional expression of TWEAK in human hepatocellular carcinoma: possible implication in cell proliferation and tumor angiogenesis.

Tomoyuki Kawakita1, Katsuya Shiraki, Yutaka Yamanaka, Yumi Yamaguchi, Yukiko Saitou, Naoyuki Enokimura, Norihiko Yamamoto, Hiroshi Okano, Kazushi Sugimoto, Kazumoto Murata, Takeshi Nakano.   

Abstract

TNF-like weak inducer of apoptosis (TWEAK) is a member of the TNF family whose transcripts are expressed in various human tissues. Since TWEAK has a variety of biological activities, we investigated TWEAK sensitivity, expression, and physiological role in human hepatocellular carcinomas (HCCs). Tweak receptor was detected in four kinds of HCC cells. TWEAK significantly promoted cell proliferation and induced nuclear factor-kappaB activation in all HCC cells. Surprisingly, we found that HCC cells constitutively express TWEAK. In addition, soluble TWEAK was detected in culture medium. We found that TWEAK also promotes cell proliferation and induces the secretion of IL-8 and MCP-1 in human umbilical vein endothelial cell. Finally, culture medium from Sh-Hep1 cells incubated with anti-TWEAK antibody significantly inhibited endothelial cell tube formation. In conclusion, these results indicate that TWEAK might play a critical role in HCC cellular proliferation using both autocrine and paracrine mechanisms, and modulate tumor-related angiogenesis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15144899     DOI: 10.1016/j.bbrc.2004.04.084

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  27 in total

Review 1.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 2.  The TWEAK-Fn14 system as a potential drug target.

Authors:  Harald Wajant
Journal:  Br J Pharmacol       Date:  2013-10       Impact factor: 8.739

3.  Low blood levels of sTWEAK are related to locoregional failure in head and neck cancer.

Authors:  Francesc Xavier Avilés-Jurado; Ximena Terra; David Gómez; Joan Carles Flores; Antoni Raventós; Elsa Maymó-Masip; Xavier León; Vicente Serrano-Gonzalvo; Joan Vendrell; Enric Figuerola; Matilde R Chacón
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-05-26       Impact factor: 2.503

4.  TWEAK/Fn14 pathway is a novel mediator of retinal neovascularization.

Authors:  Hossein Ameri; Hua Liu; Rong Liu; Yonju Ha; Adriana A Paulucci-Holthauzen; Shuqun Hu; Massoud Motamedi; Bernard F Godley; Ronald G Tilton; Wenbo Zhang
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-02-10       Impact factor: 4.799

5.  Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway.

Authors:  Sharron A N Brown; Arundhati Ghosh; Jeffrey A Winkles
Journal:  J Biol Chem       Date:  2010-04-12       Impact factor: 5.157

6.  Therapeutic potential of the TWEAK/Fn14 pathway in intractable gastrointestinal cancer.

Authors:  Ryo Yoriki; Satoru Akashi; Masayuki Sho; Takeo Nomi; Ichiro Yamato; Kiyohiko Hotta; Tomoyoshi Takayama; Sohei Matsumoto; Kohei Wakatsuki; Kazuhiro Migita; Hideo Yagita; Yoshiyuki Nakajima
Journal:  Exp Ther Med       Date:  2010-12-02       Impact factor: 2.447

7.  Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Authors:  Steffen Salzmann; Axel Seher; Johannes Trebing; Daniela Weisenberger; Alevtina Rosenthal; Daniela Siegmund; Harald Wajant
Journal:  J Biol Chem       Date:  2013-03-26       Impact factor: 5.157

8.  Fn14 hepatic progenitor cells are associated with liver fibrosis in biliary atresia.

Authors:  Lulu Zheng; Zhibao Lv; Zhenhua Gong; Qingfeng Sheng; Zhimei Gao; Yuting Zhang; Shenghua Yu; Junmei Zhou; Zhengjun Xi; Xueli Wang
Journal:  Pediatr Surg Int       Date:  2017-02-08       Impact factor: 1.827

Review 9.  TWEAK and the central nervous system.

Authors:  Manuel Yepes
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

10.  Urinary TWEAK as a biomarker of lupus nephritis: a multicenter cohort study.

Authors:  Noa Schwartz; Tamar Rubinstein; Linda C Burkly; Christopher E Collins; Irene Blanco; Lihe Su; Bernard Hojaili; Meggan Mackay; Cynthia Aranow; William Stohl; Brad H Rovin; Jennifer S Michaelson; Chaim Putterman
Journal:  Arthritis Res Ther       Date:  2009-09-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.